Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

Richard M. Bergenstal, William V. Tamborlane, Andrew Ahmann, John B. Buse, George Dailey, Stephen N. Davis, Carol Joyce, Tim Peoples, Bruce A. Perkins, John B. Welsh, Steven M. Willi, Michael A. Wood

Research output: Contribution to journalArticle

596 Citations (Scopus)

Abstract

BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. METHODS: In this 1-year, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes. Patients received recombinant insulin analogues and were supervised by expert clinical teams. The primary end point was the change from the baseline glycated hemoglobin level. RESULTS: At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P

Original languageEnglish (US)
Pages (from-to)311-320
Number of pages10
JournalNew England Journal of Medicine
Volume363
Issue number4
DOIs
StatePublished - Jul 22 2010

Fingerprint

Type 1 Diabetes Mellitus
Insulin
Glycosylated Hemoglobin A
Group Psychotherapy
Injections
Therapeutics
Randomized Controlled Trials
Technology
Glucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., ... Wood, M. A. (2010). Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. New England Journal of Medicine, 363(4), 311-320. https://doi.org/10.1056/NEJMoa1002853

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. / Bergenstal, Richard M.; Tamborlane, William V.; Ahmann, Andrew; Buse, John B.; Dailey, George; Davis, Stephen N.; Joyce, Carol; Peoples, Tim; Perkins, Bruce A.; Welsh, John B.; Willi, Steven M.; Wood, Michael A.

In: New England Journal of Medicine, Vol. 363, No. 4, 22.07.2010, p. 311-320.

Research output: Contribution to journalArticle

Bergenstal, RM, Tamborlane, WV, Ahmann, A, Buse, JB, Dailey, G, Davis, SN, Joyce, C, Peoples, T, Perkins, BA, Welsh, JB, Willi, SM & Wood, MA 2010, 'Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes', New England Journal of Medicine, vol. 363, no. 4, pp. 311-320. https://doi.org/10.1056/NEJMoa1002853
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. New England Journal of Medicine. 2010 Jul 22;363(4):311-320. https://doi.org/10.1056/NEJMoa1002853
Bergenstal, Richard M. ; Tamborlane, William V. ; Ahmann, Andrew ; Buse, John B. ; Dailey, George ; Davis, Stephen N. ; Joyce, Carol ; Peoples, Tim ; Perkins, Bruce A. ; Welsh, John B. ; Willi, Steven M. ; Wood, Michael A. / Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. In: New England Journal of Medicine. 2010 ; Vol. 363, No. 4. pp. 311-320.
@article{80f0e8d530e1426c84bd2c55c98cd784,
title = "Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes",
abstract = "BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. METHODS: In this 1-year, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes. Patients received recombinant insulin analogues and were supervised by expert clinical teams. The primary end point was the change from the baseline glycated hemoglobin level. RESULTS: At 1 year, the baseline mean glycated hemoglobin level (8.3{\%} in the two study groups) had decreased to 7.5{\%} in the pump-therapy group, as compared with 8.1{\%} in the injection-therapy group (P",
author = "Bergenstal, {Richard M.} and Tamborlane, {William V.} and Andrew Ahmann and Buse, {John B.} and George Dailey and Davis, {Stephen N.} and Carol Joyce and Tim Peoples and Perkins, {Bruce A.} and Welsh, {John B.} and Willi, {Steven M.} and Wood, {Michael A.}",
year = "2010",
month = "7",
day = "22",
doi = "10.1056/NEJMoa1002853",
language = "English (US)",
volume = "363",
pages = "311--320",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

AU - Bergenstal, Richard M.

AU - Tamborlane, William V.

AU - Ahmann, Andrew

AU - Buse, John B.

AU - Dailey, George

AU - Davis, Stephen N.

AU - Joyce, Carol

AU - Peoples, Tim

AU - Perkins, Bruce A.

AU - Welsh, John B.

AU - Willi, Steven M.

AU - Wood, Michael A.

PY - 2010/7/22

Y1 - 2010/7/22

N2 - BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. METHODS: In this 1-year, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes. Patients received recombinant insulin analogues and were supervised by expert clinical teams. The primary end point was the change from the baseline glycated hemoglobin level. RESULTS: At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P

AB - BACKGROUND: Recently developed technologies for the treatment of type 1 diabetes mellitus include a variety of pumps and pumps with glucose sensors. METHODS: In this 1-year, multicenter, randomized, controlled trial, we compared the efficacy of sensor-augmented pump therapy (pump therapy) with that of a regimen of multiple daily insulin injections (injection therapy) in 485 patients (329 adults and 156 children) with inadequately controlled type 1 diabetes. Patients received recombinant insulin analogues and were supervised by expert clinical teams. The primary end point was the change from the baseline glycated hemoglobin level. RESULTS: At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups) had decreased to 7.5% in the pump-therapy group, as compared with 8.1% in the injection-therapy group (P

UR - http://www.scopus.com/inward/record.url?scp=77954830051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954830051&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1002853

DO - 10.1056/NEJMoa1002853

M3 - Article

C2 - 20587585

AN - SCOPUS:77954830051

VL - 363

SP - 311

EP - 320

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -